Single-arm pilot: lifestyle, supplements and cell-conditioned media on biological age
In an open-label, single-arm pilot, 16 healthy adults aged 46–72 (14 completers) followed a 17-week program of lifestyle optimization, targeted supplementation and two intravenous infusions of autologous pro-regenerative cell-derived conditioned media; PhenoAge fell 2.0 years and epigenetic age 2.7 years, with no control group. [1]
Automatic summary · not editorially reviewed
The key findings
The pilot was a single-arm, open-label trial in 16 healthy adults aged 46–72, with 14 completers, testing a 17-week program of lifestyle optimization, targeted supplementation and two intravenous infusions of autologous pro-regenerative cell-derived conditioned media. [1]
PhenoAge declined by 2.0 years (p = 0.014) and epigenetic age by 2.7 years (p = 0.003), despite an already healthy baseline. [1]
The authors call the response heterogeneity and baseline iron as a potential predictor hypothesis-generating and note the pilot lacked a control or sham comparator. [1]
The source at a glance
- Study type / format
- Single-arm, open-label pilot trial (abstract).
- Population / context
- 16 healthy adults aged 46–72 (14 completers).
- Summary based on
- Study abstract
- Original publication
- June 25, 2026
Healthy adults 46–72 in a 17-week single-arm program
The abstract describes a single-arm, open-label pilot trial in 16 healthy adults aged 46–72, of whom 14 completed. The 17-week multi-modal program combined lifestyle optimization, targeted supplementation and two intravenous infusions of autologous pro-regenerative cell-derived conditioned media (APRC-CM). The authors note that human data combining lifestyle, supplementation and regenerative therapies are limited. The trial was registered as NCT07322224.
Supporting source [1]
Biological-age measures fell despite healthy baseline
At baseline the cohort was already healthy: chronological age averaged 59.3 years, PhenoAge 55.5 years and epigenetic age 57.9 years. PhenoAge declined by 2.0 years (p = 0.014), reaching 5.8 years below chronological age; epigenetic age decreased by 2.7 years (p = 0.003), widening the gap to 4.1 years. The authors interpret this as a net reversal of biological age rather than merely correcting age acceleration. Exploratory analysis found heterogeneity: a larger-response subgroup averaged a 5.1-year epigenetic-age reduction versus 0.2 years in a smaller/no-response subgroup. Lower baseline serum iron correlated with greater epigenetic-age reduction (r = 0.64; p = 0.013). No adverse events were reported.
Supporting source [1]
No control or sham; findings called hypothesis-generating
The authors state that the reductions in health-optimized individuals are notable and may indicate a lowering below expected norms rather than solely a correction of age acceleration. They describe the response heterogeneity and baseline iron metabolism as a potential predictor of response as hypothesis-generating and call for validation in larger, controlled trials. They explicitly note that this open-label, single-arm pilot lacked a control or sham comparator. The abstract does not report the composition of the supplements or the lifestyle components in detail.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This was an open-label, single-arm pilot without a control or sham comparator, so the observed changes cannot be attributed to the intervention. The sample was small (16 enrolled, 14 completers), the program combined several components, and the authors describe the response and iron findings as hypothesis-generating, requiring validation in larger controlled trials.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ortega E, Addor G, Bhatia S, Lewinsohn M, Sottas PE. · europepmc.org · June 25, 2026